Tweeti would run ferma at 2.5 ed and nolva at 10mg ed

TweetThanx Jack

Tweet

Originally posted by jack hust
i would run ferma at 2.5 ed and nolva at 10mg ed

I agree that an inhibitor and Nolva need to be run, but at 2.5mg a day of Femara, my lipid profile would be out of whack, even with the SERMS beneficial effects.

L-dex doesn't throw of my lipid panel(this is individualistic) and femara does, both are inhibitors.

If you run Femara, Iwould suggest 2.5 EOD +10mg of Nolva or 1mg ED of L-dex + 10mg Nolva

If you get blood work done, it will be relatively easy to assess your appropriate dose according to cholesterol so keep thatin mind

Tweetim sensitive to dbol, it gives me gyno very easily. test not so much though.

me id prob need to run 2.5 ed letro and 20-40ed nolva. but thats me. if im running dbol i need to be really carefull

keep in mind what letro does to nolva, it reduces the dose effectively to 40% of what your taking.

Tweet

Originally posted by superchicken


keep in mind what letro does to nolva, it reduces the dose effectively to 40% of what your taking.

why does it do that??? IS it because is stops estrogen and nolva is an estrogen??

TweetI'd run either ferma of Liquidex and 10mg Nolvadex.

I think 2.5mg ferma ED is a bit much. This is what bro's run to reverse gyno, not prevent it.

If it was me, I'd start low.. say 0.5mg liquidex ED and 10mg Nolva ED. Then up the dose if you run into problems.

Tweet

Originally posted by superchicken
keep in mind what letro does to nolva, it reduces the dose effectively to 40% of what your taking.

I trust SC's knowledge, so why I don't I just keep the Nolva on hand just incase and run the Femara 2.5mg's per day then??

TweetBump Biotch

Tweetsorry, i said it reduces nolva to 40%. i was wrong. adding 20mg ed nolva reduces LETRO BY 40%(or 37.6 if you wanna be exact) i should have looked it up cause i tend to mix things up lately.



Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE.

Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom.

This study examined whether the addition of tamoxifen to the treatment regimen of patients with advanced breast cancer being treated with the aromatase inhibitor letrozole led to any pharmacokinetic or pharmacodynamic interaction. Twelve of 17 patients completed the core period of the trial in which 2.5 mg/day letrozole was administered alone for 6 weeks and in combination with 20 mg/day tamoxifen for the subsequent 6 weeks. Patients responding to treatment continued on the combination until progression of disease or any other reason for discontinuation. Plasma levels of letrozole were measured at the end of the 6-week periods of treatment with letrozole alone and the combination and once more between 4 and 8 months on combination therapy. No further measurements were done thereafter. Hormone levels were measured at 2-week intervals throughout the core period. Marked suppression of estradiol, estrone, and estrone sulfate occurred with letrozole treatment, and this was not significantly affected by the addition of tamoxifen. However, plasma levels of letrozole were reduced by a mean 37.6% during combination therapy (P<0.0001), and this reduction persisted after 4-8 months of combination therapy. Letrozole is the first drug to be described in which this pharmacokinetic interaction occurs with tamoxifen. The mechanism is likely to be a consequence of an induction of letrozole-metabolizing enzymes by tamoxifen but was not further addressed in this study. It is possible that the antitumor efficacy of letrozole may be affected. Thus, sequential therapy may be preferable with these two drugs. It is not known whether tamoxifen interacts with other members of this class of drugs or with other drugs in combination.

TweetMy 2 cents would be to run your Femara at 2.5mg ed
And then go by feel on nolva